Sinclair IS Pharma Acquires Atlean From GSK Stiefel
LONDON (dpa-AFX) - Sinclair IS Pharma Plc. (SPH.L) announced that it has acquired Atlean, a dermal filler, from Stiefel the dermatology business of GlaxoSmithKline Plc. (GSK, GSK.L) for an undisclosed cash consideration.
Atlean combines a collagen stimulator and hyaluronic acid filler particularly for the treatment of the lower face and complements Sinclair's existing facial aesthetic brands, Sculptra and Perfectha.
Sinclair said that the acquisition enables it to add a collagen stimulator to market alongside Perfectha in its international facial aesthetics business focused on Asia-Pacific, LATAM and Russia. In Europe Atlean will provide Sinclair's aesthetic sales forces with a yet more comprehensive product range.
Atlean has not been actively marketed in Europe since 2012 and requires the European CE Mark registration to be regained which is expected to take around 9-12 months. First revenues are therefore expected in the second-half of fiscal 2015.
Copyright RTT News/dpa-AFX